Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

Wave Life Sciences to Present at the Jefferies 2018 London Healthcare Conference

November 8, 2018 at 8:59 AM EST

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 10:00 A.M. GMT.

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com.  A replay of the presentation will be archived and available at that site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Its chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. The company’s pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.

Investor Contact:

Graham Morrell
781-686-9600
gmorrell@wavelifesci.com

Media Contact:

Jose Juves
617-949-4708
jjuves@wavelifesci.com

Patient Contact:

Wendy Erler
617-949-2898
werler@wavelifesci.com

Wave Logo Swoosh-01 (005).png

Source: Wave Life Sciences